Some studies suggest that blocking CD47-SIRPα interaction may lead to off-target effects and autoimmune reactions if normal cells are inadvertently targeted. Additionally, cancer cells may develop resistance mechanisms, such as upregulation of alternative “don’t eat me” signals. Here, CD47 is linked to cancer.